ISKJ Stock Overview
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia.
Notes are coming soon
Public Joint-Stock Company "Human Stem Cells Institute" Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₽59.54|
|52 Week High||₽177.00|
|52 Week Low||₽52.52|
|1 Month Change||0%|
|3 Month Change||1.43%|
|1 Year Change||-32.86%|
|3 Year Change||391.66%|
|5 Year Change||388.03%|
|Change since IPO||306.17%|
Recent News & Updates
|ISKJ||RU Biotechs||RU Market|
Return vs Industry: ISKJ underperformed the Russian Biotechs industry which returned -7.1% over the past year.
Return vs Market: ISKJ exceeded the Russian Market which returned -38.2% over the past year.
|ISKJ Average Weekly Movement||n/a|
|Biotechs Industry Average Movement||7.8%|
|Market Average Movement||4.9%|
|10% most volatile stocks in RU Market||10.2%|
|10% least volatile stocks in RU Market||2.5%|
Stable Share Price: Insufficient data to determine ISKJ's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine ISKJ's volatility change over the past year.
About the Company
Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation.
Public Joint-Stock Company "Human Stem Cells Institute" Fundamentals Summary
|ISKJ fundamental statistics|
Is ISKJ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ISKJ income statement (TTM)|
|Cost of Revenue||₽424.68m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.24|
|Net Profit Margin||1.48%|
How did ISKJ perform over the long term?See historical performance and comparison